Scientists hunt for better ways to diagnose and treat rare bone tumors
NCT ID NCT07315542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 300 people with cartilage tumors, including both benign types and the cancer chondrosarcoma. Researchers are studying genetic changes and molecules called miRNAs to better tell these tumors apart and predict outcomes. The goal is to improve diagnosis and find new treatment targets for hard-to-treat cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARTILAGE TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
RECRUITINGBrno, South Moravian, 60200, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- Experimental drug tested for rare cancer, trial stopped early
- Blood test could spot cartilage cancer early, without radiation
- New hope for rare bone cancer? drug shows promise in early trial
- Rare bone tumor under the microscope: can we predict its behavior?
- Proton beam therapy tested for rare spine and skull base tumors